Connection

Michael Hallek to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Biomarkers, Tumor.
Michael Hallek
Connection Strength
0.152
Biomarkers, Tumor
  1. Optimizing frontline therapy of CLL based on clinical and biological factors. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):338-345.
    View in: PubMed
    Score: 0.091
  2. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leuk Lymphoma. 2018 07; 59(7):1614-1623.
    View in: PubMed
    Score: 0.023
  3. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
    View in: PubMed
    Score: 0.023
  4. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol. 1992 Jul; 65(1):1-5.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.